181 related articles for article (PubMed ID: 28831243)
21. Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart
Krol M; de Voer G; Osowski U
Patient Prefer Adherence; 2017; 11():1189-1196. PubMed ID: 28744108
[TBL] [Abstract][Full Text] [Related]
22. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
Wray S; Hayward B; Dangond F; Singer B
Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
[TBL] [Abstract][Full Text] [Related]
23. Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali
Thakur K; Biberger A; Handrich A; Rezk MF
Rheumatol Ther; 2016 Jun; 3(1):77-89. PubMed ID: 27747519
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
25. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
[TBL] [Abstract][Full Text] [Related]
26. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Lugaresi A
Expert Opin Drug Deliv; 2013 Feb; 10(2):273-83. PubMed ID: 23252744
[TBL] [Abstract][Full Text] [Related]
27. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
[TBL] [Abstract][Full Text] [Related]
28. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
Limmroth V; Bayer-Gersmann K; Mueller C; Schürks M
JMIR Form Res; 2022 Mar; 6(3):e31972. PubMed ID: 35285806
[TBL] [Abstract][Full Text] [Related]
29. Patient Experience with the SensoReady
Jathanakodi S; Both C; Brueckmann I; Rose L; Nasseri N; Raynauld JP; Narula N
Patient Prefer Adherence; 2024; 18():1107-1118. PubMed ID: 38854477
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs.
Andre AD; Brand-Schieber E; Ramirez M; Munjal S; Kumar R
Patient Prefer Adherence; 2017; 11():121-129. PubMed ID: 28176899
[TBL] [Abstract][Full Text] [Related]
31. DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment.
Pavelek Z; Novotný M; Klímová B; Peterka M; Potužník P; Kövári M; Vališ M
Curr Med Res Opin; 2021 Apr; 37(4):589-596. PubMed ID: 33538199
[TBL] [Abstract][Full Text] [Related]
32. Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey.
Ross AP; Besser C; Naval S; Stoneman D; Gaunt H; Barker N
BMC Neurol; 2023 Feb; 23(1):85. PubMed ID: 36850015
[TBL] [Abstract][Full Text] [Related]
33. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Devonshire VA; Verdun di Cantogno E
Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681
[TBL] [Abstract][Full Text] [Related]
34. Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis.
Schiff M; Koo J; Jin E; Schiller E; Day A; Stevens R; Laskar C
Adv Ther; 2016 Feb; 33(2):199-213. PubMed ID: 26833303
[TBL] [Abstract][Full Text] [Related]
35. Improving adherence to injectable disease-modifying drugs in multiple sclerosis.
Bayas A
Expert Opin Drug Deliv; 2013 Mar; 10(3):285-7. PubMed ID: 23339371
[TBL] [Abstract][Full Text] [Related]
36. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®.
Vališ M; Šarláková J; Halúsková S; Klímová B; Potužník P; Peterka M; Kuča K; Štourač P; Mareš J; Pavelek Z
Expert Opin Drug Deliv; 2020 May; 17(5):719-724. PubMed ID: 32315204
[No Abstract] [Full Text] [Related]
37. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Devonshire VA; Feinstein A; Moriarty P
BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
[TBL] [Abstract][Full Text] [Related]
38. Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart
Edo Solsona MD; Monte Boquet E; Casanova Estruch B; Poveda Andrés JL
Patient Prefer Adherence; 2017; 11():415-421. PubMed ID: 28280313
[TBL] [Abstract][Full Text] [Related]
39. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices.
Verdun di Cantogno E; Russell S; Snow T
Patient Prefer Adherence; 2011 Mar; 5():173-80. PubMed ID: 21573048
[TBL] [Abstract][Full Text] [Related]
40. Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.
Egeth M; Soosaar J; Nash P; Choquette D; Infante R; Ramey DR; Sahakian S; Lai A; Kim JJ; Wu D
Adv Ther; 2017 May; 34(5):1157-1172. PubMed ID: 28417318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
